Literature DB >> 22301151

Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

L Diomede1, S Nyoka, C Pastori, L Scotti, A Zambon, G Sherman, C M Gray, M Sarzotti-Kelsoe, L Lopalco.   

Abstract

HIV-exposed, uninfected (EUN) babies born to HIV-infected mothers are examples of natural resistance to HIV infection. In this study, we evaluated the titer and neutralizing potential of gp41-specific maternal antibodies and their correlation with HIV transmission in HIV-infected mother-child pairs. Specific gp41-binding and -neutralizing antibodies were determined in a cohort of 74 first-time mother-child pairs, of whom 40 mothers were infected with HIV subtype C. Within the infected mother cohort, 16 babies were born infected and 24 were PCR negative and uninfected at birth (i.e., exposed but uninfected). Thirty-four HIV-uninfected and HIV-unexposed mother-child pairs were included as controls. All HIV-positive mothers and their newborns showed high IgG titers to linear epitopes within the HR1 region and to the membrane-proximal (MPER) domain of gp41; most sera also recognized the disulfide loop immunodominant epitope (IDE). Antibody titers to the gp41 epitopes were significantly lower in nontransmitting mothers (P < 0.01) and in the EUN babies (P < 0.005) than in HIV-positive mother-child pairs. Three domains of gp41, HR1, IDE, and MPER, elicited antibodies that were effectively transmitted to EUN babies. Moreover, in EUN babies, epitopes overlapping the 2F5 epitope (ELDKWAS), but not the 4E10 epitope, were neutralization targets in two out of four viruses tested. Our findings highlight important epitopes in gp41 that appear to be associated with exposure without infection and would be important to consider for vaccine design.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22301151      PMCID: PMC3318605          DOI: 10.1128/JVI.06359-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.

Authors:  Bing Li; Julie M Decker; Roy W Johnson; Frederic Bibollet-Ruche; Xiping Wei; Joseph Mulenga; Susan Allen; Eric Hunter; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160.

Authors:  H Hocini; L Bélec; S Iscaki; B Garin; J Pillot; P Becquart; M Bomsel
Journal:  AIDS Res Hum Retroviruses       Date:  1997-09-20       Impact factor: 2.205

3.  Apparent enhancement of perinatal transmission of human immunodeficiency virus type 1 by high maternal anti-gp160 antibody titer.

Authors:  G Pancino; T Leste-Lasserre; M Burgard; D Costagliola; S Ivanoff; S Blanche; C Rouzioux; P Sonigo
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

4.  Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells.

Authors:  Morgane Bomsel; Claudia Pastori; Daniela Tudor; Chiara Alberti; Severine Garcia; Davide Ferrari; Adriano Lazzarin; Lucia Lopalco
Journal:  AIDS       Date:  2007-01-02       Impact factor: 4.177

5.  Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.

Authors:  Joris Hemelaar; Eleanor Gouws; Peter D Ghys; Saladin Osmanov
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

6.  Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors:  J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.

Authors:  L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

9.  Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1.

Authors:  Francis Barin; Gonzague Jourdain; Sylvie Brunet; Nicole Ngo-Giang-Huong; Supawadee Weerawatgoompa; Warit Karnchanamayul; Surabhon Ariyadej; Rawiwan Hansudewechakul; Jullapong Achalapong; Prapap Yuthavisuthi; Chaiwat Ngampiyaskul; Sorakij Bhakeecheep; Chittaphon Hemwutthiphan; Marc Lallemant
Journal:  J Infect Dis       Date:  2006-04-21       Impact factor: 5.226

10.  Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.

Authors:  Elin Solomonovna Gray; Tammy Meyers; Glenda Gray; David Charles Montefiori; Lynn Morris
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

View more
  19 in total

1.  Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.

Authors:  Sallie R Permar; Youyi Fong; Nathan Vandergrift; Genevieve G Fouda; Peter Gilbert; Robert Parks; Frederick H Jaeger; Justin Pollara; Amanda Martelli; Brooke E Liebl; Krissey Lloyd; Nicole L Yates; R Glenn Overman; Xiaoying Shen; Kaylan Whitaker; Haiyan Chen; Jamie Pritchett; Erika Solomon; Emma Friberg; Dawn J Marshall; John F Whitesides; Thaddeus C Gurley; Tarra Von Holle; David R Martinez; Fangping Cai; Amit Kumar; Shi-Mao Xia; Xiaozhi Lu; Raul Louzao; Samantha Wilkes; Saheli Datta; Marcella Sarzotti-Kelsoe; Hua-Xin Liao; Guido Ferrari; S Munir Alam; David C Montefiori; Thomas N Denny; M Anthony Moody; Georgia D Tomaras; Feng Gao; Barton F Haynes
Journal:  J Clin Invest       Date:  2015-06-08       Impact factor: 14.808

Review 2.  Antibodies for prevention of mother-to-child transmission of HIV-1.

Authors:  Genevieve G Fouda; M Anthony Moody; Sallie R Permar
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

3.  Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.

Authors:  Geert Leroux-Roels; Cathy Maes; Frédéric Clement; Frank van Engelenburg; Marieke van den Dobbelsteen; Michael Adler; Mario Amacker; Lucia Lopalco; Morgane Bomsel; Anick Chalifour; Sylvain Fleury
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

4.  M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures.

Authors:  Giuseppina Musumeci; Isabella Bon; David Lembo; Valeria Cagno; Maria Carla Re; Caterina Signoretto; Erica Diani; Lucia Lopalco; Claudia Pastori; Loïc Martin; Gilles Ponchel; Davide Gibellini; Kawthar Bouchemal
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

5.  A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.

Authors:  Lydia R Meador; Sarah A Kessans; Jacquelyn Kilbourne; Karen V Kibler; Giuseppe Pantaleo; Mariano Esteban Roderiguez; Joseph N Blattman; Bertram L Jacobs; Tsafrir S Mor
Journal:  Virology       Date:  2017-04-28       Impact factor: 3.616

6.  A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients.

Authors:  Chiara Brombin; Lorenzo Diomede; Daniela Tudor; Anne Sophie Drillet; Claudia Pastori; Elena Poli; Agostino Riva; Caterina Uberti-Foppa; Massimo Galli; Clelia Di Serio; Morgane Bomsel; Lucia Lopalco
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

7.  Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants.

Authors:  Genevieve G Fouda; Tatenda Mahlokozera; Jesus F Salazar-Gonzalez; Maria G Salazar; Gerald Learn; Surender B Kumar; S Moses Dennison; Elizabeth Russell; Katherine Rizzolo; Frederick Jaeger; Fangping Cai; Nathan A Vandergrift; Feng Gao; Beatrice Hahn; George M Shaw; Christina Ochsenbauer; Ronald Swanstrom; Steve Meshnick; Victor Mwapasa; Linda Kalilani; Susan Fiscus; David Montefiori; Barton Haynes; Jesse Kwiek; S Munir Alam; Sallie R Permar
Journal:  Retrovirology       Date:  2013-01-10       Impact factor: 4.602

Review 8.  Maternal Intervention to Prevent Mother-to-Child Transmission of HIV: Moving Beyond Antiretroviral Therapy.

Authors:  Jesse F Mangold; Ria Goswami; Ashley N Nelson; David R Martinez; Genevieve G Fouda; Sallie R Permar
Journal:  Pediatr Infect Dis J       Date:  2021-05-01       Impact factor: 3.806

Review 9.  The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?

Authors:  Martine Braibant; Francis Barin
Journal:  Retrovirology       Date:  2013-10-07       Impact factor: 4.602

10.  Maternal Neutralization-Resistant Virus Variants Do Not Predict Infant HIV Infection Risk.

Authors:  Caitlin Milligan; Maxwel M Omenda; Vrasha Chohan; Katherine Odem-Davis; Barbra A Richardson; Ruth Nduati; Julie Overbaugh
Journal:  mBio       Date:  2016-02-02       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.